Compare CYN & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYN | CTXR |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 18.9M |
| IPO Year | 2021 | 2010 |
| Metric | CYN | CTXR |
|---|---|---|
| Price | $1.64 | $0.63 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 257.8K | ★ 870.3K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $368,138.00 | N/A |
| Revenue This Year | $3,359.28 | N/A |
| Revenue Next Year | $347.47 | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $0.57 |
| 52 Week High | $41.54 | $2.38 |
| Indicator | CYN | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 38.78 |
| Support Level | $1.49 | N/A |
| Resistance Level | $1.76 | $0.99 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 33.59 | 13.59 |
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.